Valerie Malyvanh Jansen - 15 Feb 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
15 Feb 2025
Net transactions value
-$3,485
Form type
4
Filing time
19 Feb 2025, 16:25:05 UTC
Previous filing
08 Oct 2024
Next filing
30 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +17,500 17,500 15 Feb 2025 Direct F1
transaction ELEV Common Stock Tax liability $3,485 -5,189 -30% $0.6717 12,311 15 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +275,000 $0.000000 275,000 15 Feb 2025 Common Stock 275,000 $0.6717 Direct F2
transaction ELEV Restricted Stock Unit Options Exercise $0 -17,500 -25% $0.000000 52,500 15 Feb 2024 Common Stock 17,500 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4 The RSUs do not expire; they either vest or are canceled prior to the vesting date.